Compounds > rp 73401
Page last updated: 2024-09-04

rp 73401 and Inflammation

rp 73401 has been researched along with Inflammation in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's5 (83.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alonso, JM; Andrés, JI; Boeckx, G; Cools, M; de Chaffoy, D; De Clerck, F; Deroose, F; Díaz, A; Diels, G; Fernández, J; Freyne, EJ; Iturrino, L; Martínez, P; Matesanz, E; Megens, A; Peeters, D; Petit, D; Somers, M; Stoppie, P; Van Wauwe, J1
Baik, KU; Cho, JY; Kim, HP; Lee, JG; Park, JS; Park, MH; Yoo, ES1
Husfeld, C; Ji, YH; Klein, U; Linnevers, C; McCluskie, K; Thomas, GR; Yang, A1
de Visser, YP; Laghmani, EH; Nieuwland, K; van Wijngaarden, S; Wagenaar, GT; Walther, FJ1
Battram, CH; Jordan, R; Lewis, SA; Raeburn, D; Sharma, S; Souness, JE; Tomkinson, A; Underwood, SL; Webber, SE; Woodman, VR1
Egging, EA; Gullikson, GW; Hammerbeck, DM; Hupperts, AM; Johnson, DD; McGurran, SM; Radziszewski, PL1

Other Studies

6 other study(ies) available for rp 73401 and Inflammation

ArticleYear
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
    Bioorganic & medicinal chemistry letters, 2002, Feb-25, Volume: 12, Issue:4

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Administration, Topical; Animals; Anti-Inflammatory Agents; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Dose-Response Relationship, Drug; Ear Diseases; Enzyme Inhibitors; Humans; Imidazoles; Inflammation; Inhibitory Concentration 50; Rats; Structure-Activity Relationship

2002
Differential effect of phosphodiesterase IV inhibitor RP73401 on various inflammatory and immune responses relevent to rheumatoid arthritis.
    Pharmacological research, 2004, Volume: 49, Issue:5

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arachidonic Acid; Arthritis, Experimental; Arthritis, Rheumatoid; Benzamides; Cell Physiological Phenomena; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Drug Evaluation, Preclinical; Ear Diseases; Edema; Humans; Immunity, Active; Inflammation; Lipopolysaccharides; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Nitric Oxide; Pyridines; Rats; Rats, Sprague-Dawley; Spleen; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha; U937 Cells

2004
Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:1

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Cytokines; Humans; Inflammation; Interleukin-8; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Phosphodiesterase Inhibitors; Pyridines

2006
Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury.
    The European respiratory journal, 2008, Volume: 31, Issue:3

    Topics: Animals; Animals, Newborn; Benzamides; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Gene Expression Profiling; Humans; Infant, Newborn; Inflammation; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Alveoli; Pulmonary Fibrosis; Pyridines; Rats; Rats, Wistar; Respiration, Artificial; Respiratory Distress Syndrome; Rolipram

2008
Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor.
    British journal of pharmacology, 1994, Volume: 113, Issue:4

    Topics: Albuterol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Bronchial Hyperreactivity; Bronchial Spasm; Bronchodilator Agents; Capillary Permeability; Guinea Pigs; Hemodynamics; Histamine; Inflammation; Male; Muscle Contraction; Muscle, Smooth; Phosphodiesterase Inhibitors; Platelet Activating Factor; Pyridines; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Rolipram

1994
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
    Inflammation, 2000, Volume: 24, Issue:4

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Androstadienes; Animals; Asthma; Beclomethasone; Benzamides; Budesonide; Cyclic Nucleotide Phosphodiesterases, Type 4; Dexamethasone; Dextrans; Disease Models, Animal; Enzyme Inhibitors; Eosinophil Peroxidase; Eosinophils; Fluticasone; Glucocorticoids; Guinea Pigs; Inflammation; Lung; Male; Ovalbumin; Peroxidases; Pyridines; Rats; Rats, Sprague-Dawley; Rolipram

2000